UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________________________________________________

FORM 8-K

__________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 4 12, 2026

__________________________________________________________________________________________

Zevra Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

__________________________________________________________________________________________

Delaware	001-36913	20-5894398
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Federal Street, Boston, MA		~~02110~~2110
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (~~888~~321) ~~958~~939-~~1253~~3416

(Former Name or Former Address, if Changed Since Last Report)

1180 Celebration Boulevard, Suite 103, Celebration, FL 34747

__________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ZVRA	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.~~02 Results~~01 Entry ofinto ~~Operations~~a ~~and~~Material ~~Financial~~Definitive ~~Condition~~Agreement.

On March 9 13, 2026, Zevra Therapeutics, Inc.~~, a Delaware corporation~~ (~~"Zevra" or "~~the “Company"”), ~~issued~~entered ainto ~~press~~an ~~release~~Asset ~~announcing~~Purchase ~~its financial results~~ and ~~corporate~~Settlement ~~updates~~Agreement ~~for~~ (the ~~fourth~~“Agreement”) ~~quarter ended~~with ~~December 31,~~Commave ~~2025,~~Therapeutics asSA ~~well~~(“Commave”) asto ~~information~~sell ~~regarding a~~certain ~~conference~~assets ~~call~~of ~~and~~the ~~audio~~Company ~~webcast~~ to ~~discuss~~Commave ~~its financial results~~ and ~~corporate~~to ~~updates~~resolve ~~scheduled~~litigation ~~for~~pending ~~Monday,~~in ~~March 9,~~the ~~2026,~~Court atof ~~4:30 p.m.~~Chancery ~~ET.~~of Athe ~~copy~~State of ~~the~~Delaware ~~press~~captioned ~~release~~Commave ~~is furnished~~Therapeutics asSA ~~Exhibit 99~~v.~~1 to~~ ~~this~~Zevra ~~Current~~Therapeutics, ~~Report~~Inc., onC.A. ~~Form~~No. 82024-~~K. The~~0920-LWW ~~information contained in~~ (the ~~press~~“Litigation”) ~~release, furnished~~related asto ~~Exhibit~~claims ~~99.1~~arising ~~shall~~under ~~not~~the beCollaboration ~~deemed~~and ~~“filed"~~License ~~for~~Agreement ~~purposes~~between ~~of Section 18 of~~ the ~~Securities~~parties ~~Exchange~~dated ~~Act~~September of3, ~~1934~~2019, as amended, ~~and~~(the is“AZSTARYS ~~not~~License ~~incorporated~~Agreement”). byThe ~~reference~~AZSTARYS ~~into~~License ~~any~~Agreement ofgoverned ~~Zevra's filings under~~ the ~~Securities~~collaboration ~~Act~~between ofthe ~~1933,~~Company asand ~~amended,~~Commave ~~whether~~relating ~~made~~to ~~before or after~~ the ~~date~~development ~~hereof,~~and ~~except~~commercialization asof ~~shall~~AZSTARYS® beand ~~expressly~~product ~~set~~candidates ~~forth~~containing byserdexmethylphenidate ~~specific reference in any such filing~~(“SDX”).

~~Item~~Pursuant to the Agreement, Commave has agreed to pay the Company a total of $50.0 million in cash, and the Company has agreed to sell, transfer, and assign to Commave, free and clear of all encumbrances, all of the Company's right, title, and interest in and to certain assets relating to the Company's SDX portfolio, including AZSTARYS® (KP415) and KP1077. The sale of the transferred assets was effective upon execution of the Agreement on March 13, 2026. Commave is obligated to pay the Company $25.0 million upon execution of the Agreement, $20.0 million no later than ten business days following the effective date of the Agreement, and $5.~~02 Departure~~0 million within three days following the delivery of ~~Directors~~certain manufacturing records and patent books and records. In addition, under the Agreement, the Company and Commave have agreed to terminate the AZSTARYS License Agreement in its entirety, and each party has released the other from any and all claims for any acts or ~~Certain~~omissions ~~Officers;~~arising ~~Election~~prior to or as of ~~Directors;~~the ~~Appointment~~effective date of ~~Certain~~the ~~Officers;~~Agreement ~~Compensatory~~related ~~Arrangements~~to ofor ~~Certain~~arising ~~Officers~~from the claims asserted in the Litigation or the AZSTARYS License Agreement.

OnUnder ~~March~~the 4Agreement, ~~2026,~~ the Company ~~appointed~~has ~~Justin~~also ~~Renz~~granted asto ~~Chief~~Commave ~~Financial Officer~~ and ~~Treasurer,~~its ~~effective~~affiliates ~~March~~a 9worldwide, ~~2026~~royalty-free, ~~and~~fully aspaid-up, ~~principal~~transferable, ~~financial officer~~perpetual, ~~effective March 10~~non-terminable, ~~2026.~~and Onirrevocable ~~March 5~~license, ~~2026,~~with the ~~Company~~right ~~issued~~to asublicense, ~~press~~for ~~release announcing~~ the ~~appointment~~purpose of ~~Mr.~~developing, ~~Renz~~manufacturing, ~~as Chief Financial Officer~~commercializing, aor ~~copy~~otherwise ofexploiting ~~which~~SDX isand ~~attached~~SDX ~~hereto~~products asunder ~~Exhibit~~patents ~~99.2~~ and isknow-how ~~incorporated~~retained by ~~reference~~the ~~herein.~~Company ~~There~~that ~~are~~cover noSDX ~~family relationships between Mr. Renz~~ and ~~any directors or executive officers of~~ the ~~Company.~~SDX ~~The Company is not aware of any transaction involving Mr~~products. ~~Renz requiring disclosure under Item 404(a) of Regulation S-K.~~

~~Mr.~~Within ~~Renz,~~three ~~age~~business ~~54,~~days ~~served~~following asthe ~~Chief~~effective ~~Financial~~date ~~and Operations Officer~~ of ~~Ardelyx,~~the ~~Inc.~~Agreement, athe ~~commercial-stage~~parties ~~biopharmaceutical~~are ~~company,~~required ~~from January 2023~~ to ~~October~~file ~~2025,~~a ~~and~~stipulation ~~served~~of asdismissal ~~its~~with ~~Chief~~prejudice ~~Financial Officer from June 2020 to January 2023. Beginning in 2017, Mr. Renz held various positions~~ of ~~increasing responsibility at Correvio Pharma Corp, a specialty pharmaceutical company, most recently as its President and Chief Financial Officer at~~ the ~~time~~Litigation ofwith ~~its acquisition by Advanz Pharma in May 2020. From 2014 to 2017, Mr. Renz was~~ the ~~Executive~~Court ~~Vice President and Chief Financial Officer~~ of ~~Karyopharm~~Chancery ~~Therapeutics, Inc. Prior to that, from 2006 to 2014, Mr. Renz held a variety~~ of ~~financial positions with Zalicus Pharmaceuticals Ltd., a biopharmaceutical company, including most recently as Executive Vice President and Chief Financial Officer at~~ the ~~time~~State of ~~its acquisition by Epirus Biopharmaceuticals, Inc~~Delaware. ~~in 2014.~~

InThe ~~connection~~Agreement ~~with~~contains ~~his~~customary ~~employment,~~representations ~~Mr. Renz~~ and ~~the Company have entered into an employment agreement (the “Employment Agreement”) effective as of March 9~~warranties, ~~2026.~~indemnification ~~Under the Employment Agreement~~provisions, his annualized base salary will be $520,000. Mr. Renz will be eligible to receive an annual performance bonus with a bonus target of 45% of his annual base salary. Mr. Renz will also receive an option to purchase 300,000 shares of the Company’s common stock (the “Equity Award”) pursuant to and inconfidentiality ~~accordance with the terms and conditions of Company’s Amended and Restated 2023 Employment Inducement Award Plan~~covenants. The Equity Award will have an exercise price equal to the fair market value of a share of the Company’s common stock on the date of grant and will vest over four years, with one-fourth vesting on each of the first four anniversaries of the date Mr. Renz begins his employment with the Company. Mr. Renz will also be eligible to receive an annual equity grant as part of the Company’s annual equity award cycle beginning in 2027.

IfItem Mr1.02 Termination ~~Renz’s employment is terminated by the Company without cause or he resigns for good reason, he will receive continued payment~~ of his base salary for twelve months (the “Severance Period”), payment of an amount equal to his prorated annual target bonus for the year of termination, and acceleration of the vesting of stock awards that would have vested during the Severance Period. Receipt of the foregoing termination benefits will be subject to Mr. Renz’s execution of a ~~separation~~Material ~~agreement,~~Definitive ~~including certain restrictive covenants and a general release of all claims, in a form acceptable to the Company~~Agreement.

~~The~~On ~~foregoing~~March ~~description~~12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”). The Credit Agreement provided for a senior secured loan facility in an aggregate principal ~~terms~~amount of up to $100.0 million, of which $60.0 million was funded on April 5, 2024. As of the ~~Employment~~date of repayment, the aggregate principal amount outstanding under the Credit Agreement iswas ~~qualified~~approximately $63.0 million (which includes accrued paid-in-kind ~~its~~interest ~~entirety~~of byapproximately ~~reference~~$3.0 million), plus accrued and unpaid cash interest. The Term Loans were scheduled to mature on April 5, 2029. Upon repayment, the ~~Employment~~Credit Agreement and all related loan documents were terminated, aand ~~copy~~all liens and security interests granted thereunder on substantially all of ~~which~~the isCompany's ~~attached~~and ascertain ~~Exhibit~~of ~~10.1~~its subsidiaries' current and ~~incorporated~~future byassets ~~reference~~were ~~herein~~released.

~~Effective~~The asforegoing description of ~~March~~the ~~10,~~Credit ~~2026,~~Agreement ~~Mr.~~does ~~Renz~~not ~~will~~purport ~~begin~~to ~~serving~~be ascomplete ~~principal~~and ~~financial~~is ~~officer,~~qualified ~~and~~in ~~Timothy~~its ~~Sangiovanni~~entirety by reference to the full text of the Credit Agreement, a copy of which was filed as Exhibit 10.16 to the Company’'s ~~Senior~~Quarterly ~~Vice~~Report ~~President,~~on ~~Finance~~Form ~~and~~10-Q ~~Corporate~~filed ~~Controller,~~with ~~principal~~the ~~accounting~~Securities ~~officer~~ and ~~current~~Exchange ~~principal~~Commission ~~financial~~on ~~officer~~May 9, ~~will~~2024 ~~cease~~and ~~serving~~is asincorporated ~~the~~herein ~~principal~~by ~~financial officer~~reference.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On March 16, 2026, the Company issued a press release announcing the Agreement. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


(d)			Exhibits

Exhibit No.						Description
10.1						Employment Agreement, effective as of March 9, 2026, by and between Justin Renz and the Company
99.1						Press Release dated March 16, 2026
99.1						Press Release dated March 9, 2026
99.2						Press Release dated March 5, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Zevra Therapeutics, Inc.
Date: March 9, 2026	By:	/s/ Timothy J. Sangiovanni
Date: March 16, 2026	By:	/s/ Rahsaan Thompson
		Timothy J. Sangiovanni, CPA
		Rahsaan Thompson
		Senior Vice President, Finance and Corporate Controller
		Chief Legal Officer and Secretary

Filing Compare · ZEVRA THERAPEUTICS, INC.